Jazz Pharmaceuticals (JAZZ) PT Raised to $175 at Deutsche Bank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Jazz Pharmaceuticals (JAZZ) PT Raised to $182 at Wells Fargo
May 15, 2018 2:01 PM EDTWells Fargo raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $182.00 (from $176.00) while maintaining an Outperform rating following Q1 results.
Analyst David Maris notes their 2018 EPS estimate is now $13.00 (vs prior $12.91).
... More